Patents by Inventor Carmelita Garcia
Carmelita Garcia has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20140044782Abstract: Sustained release dosage forms for twice daily oral dosing to a human patient for providing relief from pain are provided. The sustained release dosage form comprises an immediate release component and a sustained release component, wherein the immediate release component and the sustained release component collectively contain a therapeutically effective amount of an opioid analgesic and a therapeutically effective amount of nonopioid analgesic. In a preferred embodiment, the nonopioid analgesic is acetaminophen and the opioid analgesic is hydrocodone and pharmaceutically acceptable salts thereof, and in preferred embodiments, the pharmaceutically acceptable salt is bitartrate. The dosage forms produce plasma profiles in a patient characterized by a Cmax for hydrocodone of between about 0.6 ng/mL/mg to about 1.4 ng/mL/mg and an AUC for hydrocodone of between about 9.1 ng*hr/mL/mg to about 19.9 ng*hr/mL/mg (per mg hydrocodone bitartrate administered) and a Cmax for acetaminophen of between about 2.Type: ApplicationFiled: October 21, 2013Publication date: February 13, 2014Applicant: ALZA CORPORATIONInventors: Evangeline Cruz, Atul D. Ayer, Brenda J. Pollock, Carmelita Garcia, Sherry Li, Alfredo M. Wong, Lawrence G. Hamel, Cheri Enders Klein, Yihong Qiu, Ye Huang
-
Publication number: 20120251590Abstract: Sustained release dosage forms for twice daily oral dosing to a human patient for providing relief from pain are provided. The sustained release dosage form comprises an immediate release component and a sustained release component, wherein the immediate release component and the sustained release component collectively contain a therapeutically effective amount of an opioid analgesic and a therapeutically effective amount of nonopioid analgesic.Type: ApplicationFiled: March 30, 2012Publication date: October 4, 2012Inventors: Evangeline Cruz, Atul D. Ayer, Brenda J. Pollock, Carmelita Garcia, Sherry Li, Alfredo M. Wong, Lawrence G. Hamel, Cheri Enders Klein, Yihong Qiu, Ye Huang
-
Patent number: 8246986Abstract: Aqueous drug coatings including at least one insoluble drug, wherein the insoluble drug accounts for about 85 wt % to about 97 wt % of the drug coatings are described. Such drug coatings may include only one insoluble drug, two or more insoluble drugs, or one or more insoluble drugs in combination with one or more soluble drugs.Type: GrantFiled: September 23, 2004Date of Patent: August 21, 2012Assignee: Alza CorporationInventors: Evangeline Cruz, Gregory Ruhlmann, Brenda Pollock, Sherry Li, Carmelita Garcia, Alfredo M. Wong, Ryan Bronz, Tracy Fink, David Edgren
-
Patent number: 8226979Abstract: The present invention is directed to aqueous drug coatings that include at least one insoluble drug, wherein the drug accounts for about 85 wt % to about 97 wt % of the drug coatings. A drug coating according to the present invention may include only one insoluble drug, two or more insoluble drugs, or one or more insoluble drugs in combination with one or more soluble drugs. The present invention also includes drug coating formulations suitable for providing drug coatings according to the present invention and dosage forms that include a drug coating according to the present invention.Type: GrantFiled: April 11, 2011Date of Patent: July 24, 2012Assignee: Alza CorporationInventors: Evangeline Cruz, Gregory Ruhlmann, Brenda Pollock, Sherry Li, Carmelita Garcia, Alfredo M. Wong, Ryan Bronz, Tracy Fink, David Edgren
-
Publication number: 20120165358Abstract: Sustained release dosage forms for twice daily oral dosing to a human patient for providing relief from pain are provided. The sustained release dosage form comprises an immediate release component and a sustained release component, wherein the immediate release component and the sustained release component collectively contain a therapeutically effective amount of an opioid analgesic and a therapeutically effective amount of nonopioid analgesic. In a preferred embodiment, the nonopioid analgesic is acetaminophen and the opioid analgesic is hydrocodone and pharmaceutically acceptable salts thereof, and in preferred embodiments, the pharmaceutically acceptable salt is bitartrate. The dosage forms produce plasma profiles in a patient characterized by a Cmax for hydrocodone of between about 0.6 ng/mL/mg to about 1.4 ng/mL/mg and an AUC for hydrocodone of between about 9.1 ng*hr/mL/mg to about 19.9 ng*hr/mL/mg (per mg hydrocodone bitartrate administered) and a Cmax for acetaminophen of between about 2.Type: ApplicationFiled: November 18, 2011Publication date: June 28, 2012Inventors: Evangeline Cruz, Atul D. Ayer, Brenda J. Pollock, Carmelita Garcia, Sherry Li, Alfredo M. Wong, Lawrence G. Hamel, Cheri Enders Klein, Yihong Qiu, Ye Huang
-
Publication number: 20120165361Abstract: The present invention is directed to aqueous drug coatings that include at least one insoluble drug, wherein the drug accounts for about 85 wt % to about 97 wt % of the drug coatings. A drug coating according to the present invention may include only one insoluble drug, two or more insoluble drugs, or one or more insoluble drugs in combination with one or more soluble drugs. The present invention also includes drug coating formulations suitable for providing drug coatings according to the present invention and dosage forms that include a drug coating according to the present invention.Type: ApplicationFiled: March 6, 2012Publication date: June 28, 2012Inventors: Evangeline Cruz, Gregory Ruhlmann, Brenda Pollock, Sherry Li, Carmelita Garcia, Alfredo M. Wong, Ryan Bronz, Tracy Fink, David Edgren
-
Publication number: 20110318392Abstract: The present invention is directed to aqueous drug coatings that include at least one insoluble drug, wherein the drug accounts for about 85 wt % to about 97 wt % of the drug coatings. A drug coating according to the present invention may include only one insoluble drug, two or more insoluble drugs, or one or more insoluble drugs in combination with one or more soluble drugs. The present invention also includes drug coating formulations suitable for providing drug coatings according to the present invention and dosage forms that include a drug coating according to the present invention.Type: ApplicationFiled: April 11, 2011Publication date: December 29, 2011Inventors: Evangeline Cruz, Gregory Ruhlmann, Brenda Pollock, Sherry Li, Carmelita Garcia, Alfredo M. Wong, Ryan Bronz, Tracy Fink, David Edgren
-
Publication number: 20100221293Abstract: Sustained release dosage forms for twice daily oral dosing to a human patient for providing relief from pain are provided. The sustained release dosage form comprises an immediate release component and a sustained release component, wherein the immediate release component and the sustained release component collectively contain a therapeutically effective amount of an opioid analgesic and a therapeutically effective amount of nonopioid analgesic. In a preferred embodiment, the nonopioid analgesic is acetaminophen and the opioid analgesic is hydrocodone and pharmaceutically acceptable salts thereof, and in preferred embodiments, the pharmaceutically acceptable salt is bitartrate. The dosage forms produce plasma profiles in a patient characterized by a Cmax for hydrocodone of between about 0.6 ng/mL/mg to about 1.4 ng/mL/mg and an AUC for hydrocodone of between about 9.1 ng*hr/mL/mg to about 19.9 ng*hr/mL/mg (per mg hydrocodone bitartrate administered) and a Cmax for acetaminophen of between about 2.Type: ApplicationFiled: March 2, 2010Publication date: September 2, 2010Inventors: Evangeline Cruz, Atul D. Ayer, Brenda J. Pollock, Carmelita Garcia, Sherry Li, Alfredo M. Wong, Lawrence G. Hamel, Cheri Enders Klein, Yihong Qiu, Ye Huang
-
Publication number: 20100196425Abstract: A sustained release dosage form is provided comprising a pharmaceutically active agent and pharmaceutically acceptable salts thereof and adapted to release as an erodible solid over a prolonged period of time, wherein the dosage form provides burst release of the pharmaceutically active agent without the use of an immediate release drug coating. The dosage form is able to deliver high doses of poorly soluble or slowly dissolving active agents at a controlled rate. Methods of using the dosage forms to treat disease or conditions in human patients are also disclosed.Type: ApplicationFiled: January 6, 2010Publication date: August 5, 2010Inventors: Evangeline Cruz, Sherry Li, Atul D. Ayer, Brenda J. Pollock, Gregory C. Ruhlmann, Carmelita Garcia, Alfredo M. Wong, Lawrence G. Hamel
-
Publication number: 20060251721Abstract: Sustained release dosage forms for twice daily oral dosing to a human patient for providing relief from pain are provided. The sustained release dosage form comprises an immediate release component and a sustained release component, wherein the immediate release component and the sustained release component collectively contain a therapeutically effective amount of an opioid analgesic and a therapeutically effective amount of nonopioid analgesic. In a preferred embodiment, the nonopioid analgesic is acetaminophen and the opioid analgesic is hydrocodone and pharmaceutically acceptable salts thereof, and in preferred embodiments, the pharmaceutically acceptable salt is bitartrate. The dosage forms produce plasma profiles in a patient characterized by a Cmax for hydrocodone of between about 0.6 ng/mL/mg to about 1.4 ng/mL/mg and an AUC for hydrocodone of between about 9.1 ng*hr/mL/mg to about 19.9 ng*hr/mL/mg (per mg hydrocodone bitartrate administered) and a Cmax for acetaminophen of between about 2.Type: ApplicationFiled: June 30, 2006Publication date: November 9, 2006Inventors: Evangeline Cruz, Atul Ayer, Brenda Pollock, Carmelita Garcia, Sherry Li, Alfredo Wong, Lawrence Hamel, Cheri Klein, Yihong Qiu, Ye Huang
-
Publication number: 20050158382Abstract: Sustained release dosage forms for twice daily oral dosing to a human patient for providing relief from pain are provided. The sustained release dosage form comprises an immediate release component and a sustained release component, wherein the immediate release component and the sustained release component collectively contain a therapeutically effective amount of an opioid analgesic and a therapeutically effective amount of nonopioid analgesic. In a preferred embodiment, the nonopioid analgesic is acetaminophen and the opioid analgesic is hydrocodone and pharmaceutically acceptable salts thereof, and in preferred embodiments, the pharmaceutically acceptable salt is bitartrate. The dosage forms produce plasma profiles in a patient characterized by a Cmax for hydrocodone of between about 0.6 ng/mL/mg to about 1.4 ng/mL/mg and an AUC for hydrocodone of between about 9.1 ng*hr/mL/mg to about 19.9 ng*hr/mL/mg (per mg hydrocodone bitartrate administered) and a Cmax for acetaminophen of between about 2.Type: ApplicationFiled: September 24, 2004Publication date: July 21, 2005Inventors: Evangeline Cruz, Atul Ayer, Brenda Pollock, Carmelita Garcia, Sherry Li, Alfredo Wong, Lawrence Hamel, Cheri Klein, Yihong Qiu, Ye Huang
-
Publication number: 20050112195Abstract: The present invention is directed to aqueous drug coatings that include at least one insoluble drug, wherein the drug accounts for about 85 wt % to about 97 wt % of the drug coatings. A drug coating according to the present invention may include only one insoluble drug, two or more insoluble drugs, or one or more insoluble drugs in combination with one or more soluble drugs. The present invention also includes drug coating formulations suitable for providing drug coatings according to the present invention and dosage forms that include a drug coating according to the present invention.Type: ApplicationFiled: September 23, 2004Publication date: May 26, 2005Inventors: Evangeline Cruz, Gregory Ruhlmann, Brenda Pollock, Sherry Li, Carmelita Garcia, Alfredo Wong, Ryan Bronz, Tracy Fink, David Edgren
-
Publication number: 20050089570Abstract: A sustained release dosage form is provided comprising a pharmaceutically active agent and pharmaceutically acceptable salts thereof and adapted to release as an erodible solid over a prolonged period of time, wherein the dosage form provides burst release of the pharmaceutically active agent without the use of an immediate release drug coating. The dosage form is able to deliver high doses of poorly soluble or slowly dissolving active agents at a controlled rate. Methods of using the dosage forms to treat disease or conditions in human patients are also disclosed.Type: ApplicationFiled: September 24, 2004Publication date: April 28, 2005Inventors: Evangeline Cruz, Sherry Li, Atul Ayer, Brenda Pollock, Gregory Ruhlmann, Carmelita Garcia, Alfredo Wong, Lawrence Hamel